Phase 3 intranasal carbetocin in Prader-Willi syndrome (H-45038 )
Study Goal(s): This Phase 3 study is designed to test the effectiveness and tolerability of intranasal carbetocin (LV-101),an oxytocin analog, in participants with Prader-Willi syndrome (PWS).
Investigators: Dr. Williams (site principal investigator), Katherine Hwu, M.D. (co-investigator)
Supported by: Levo Therapeutics